Skip to main content

Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer

Cancer Chemotherapy and Pharmacology volume 68, pages 1497–1505 (2011)Cite this article

Abstract

Purpose

The aim of this study was to evaluate efficacy and feasibility of a combination of weekly docetaxel and cisplatin administered concomitantly with radiotherapy followed by surgery in addition to consolidation chemotherapy with docetaxel and cisplatin administered every 3 weeks in stage III non-small cell lung cancer (NSCLC).

Methods

A total of 31 histologically proven, locally advanced (stage IIIA-N2 = 9, stage IIIB-T4N0-2 = 22) NSCLC patients were investigated. After administration of 4–6 cycles of weekly docetaxel (20 mg/m2) and weekly cisplatin (20 mg/m2) concurrently with radiotherapy, patients underwent operation if their disease was appropriately downstaged. Combination chemotherapy with docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks was administered as a consolidation regimen. The treatment response, toxicity, time to progression (TTP) and overall survival (OS) were evaluated.

Results

After concomitant chemoradiotherapy, complete response and partial response occurred in 16.1 and 67.7% of patients, respectively. Thirteen percentage of patients progressed on treatment, and 3.2% had stable disease. Grade 3–4 hematologic and skin toxicities did not occur, whereas 17.9% of them experienced grade 3–4 oesophageal toxicity. Grade 3 pulmonary toxicity and grade 3–4 emesis developed in 9.7 and 6.4% of patients, respectively. Thirteen responsive patients (41.9%) underwent surgery. The toxicity of consolidation chemotherapy was tolerable. Median OS and TTP were 22 ± 5 (range 13–31) and 12 ± 3 (range 7–17) months, respectively. Median follow-up was 22 (range 2–57) months.

Conclusions

Weekly administration of docetaxel and cisplatin concurrently with radiotherapy followed by consolidation chemotherapy is an effective treatment with acceptable toxicity for patients with locally advanced NSCLC especially in combination with surgery.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American society of clinical oncology. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353

    PubMed  Article  Google Scholar 

  2. Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR, Turrisi A III (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group, and southwest oncology group. Chest 117:358–364

    PubMed  Article  CAS  Google Scholar 

  3. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699

    PubMed  CAS  Google Scholar 

  4. Goodgame B, Stinchcombe TE, Simon G, Wozniak A, Govindan R (2009) Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American society of clinical oncology (2009). J Thorac Oncol 4:1293–1300

    PubMed  Article  Google Scholar 

  5. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2:845–853

    PubMed  Article  Google Scholar 

  6. Milas L (2002) Docetaxel/radiation combinations: rationale and preclinical findings. Clin Lung Cancer 3:29–36

    Article  Google Scholar 

  7. Vokes EE, Crawford J, Bogart J, Socinski MA, Clamon G, Green MR (2005) Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 11:5045–5050

    Article  Google Scholar 

  8. Pezzetta E, Stupp R, Zouhair A, Guillou L, Taffé P, von Briel C, Krueger T, Ris HB (2005) Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg 27:1092–1098

    PubMed  Article  Google Scholar 

  9. Stinchcombe TE, Fried D, Morris DE, Socinski MA (2006) Combined modality therapy for stage III non-small cell lung cancer. Oncologist 11:809–823

    PubMed  Article  CAS  Google Scholar 

  10. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181–2190

    PubMed  Article  Google Scholar 

  11. Ulutin HC, Güden M, Oysul K, Sürenkök S, Pak Y (2000) Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer. Radiat Med 18:93–96

    PubMed  CAS  Google Scholar 

  12. Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex F, Pérol M, Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: groupe Lyon-Saint-Etienne d’oncologie thoracique-groupe français de pneumo-cancérologie NPC 95–01 study. J Clin Oncol 23:5910–5917

    PubMed  Article  CAS  Google Scholar 

  13. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46:87–98

    PubMed  Article  Google Scholar 

  14. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883–5891

    PubMed  Article  CAS  Google Scholar 

  15. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, Nishikawa K, Ishihara H (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 40:79–84

    PubMed  Article  Google Scholar 

  16. Harada H, Yamamoto N, Takahashi T, Endo M, Murakami H, Tsuya A, Nakamura Y, Ono A, Igawa S, Shukuya T, Tamiya A, Nishimura T (2009) Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer. Int J Clin Oncol 14:507–512

    PubMed  Article  Google Scholar 

  17. Nakamura M, Koizumi T, Hayasaka M, Yasuo M, Tsushima K, Kubo K, Gomi K, Shikama N (2009) Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 63:1091–1096

    PubMed  Article  CAS  Google Scholar 

  18. Beckmann G, Fietkau R, Huber RM, Kleine P, Schmidt M, Semrau S, Aubert D, Fittipaldo A, Flentje M (2006) Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study. Onkologie 29:137–142

    PubMed  Article  CAS  Google Scholar 

  19. Naito Y, Kubota K, Nihei K, Fujii T, Yoh K, Niho S, Goto K, Ohmatsu H, Saijo N, Nishiwaki Y (2008) Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer. J Thorac Oncol 3:617–622

    PubMed  Article  Google Scholar 

  20. Yamamoto N, Nishimura Y, Nakagawa K, Matsui K, Fukuoka M (2006) Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Cancer Chemother Pharmacol 58:285–291

    PubMed  Article  CAS  Google Scholar 

  21. Mudad R, Ramsey M, Kovitz K, Curiel TJ, Hartz R, Nedzi LL, Weiner RS, Zakris EL (2003) Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 39:173–177

    PubMed  Article  Google Scholar 

  22. Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, Hiraki S, Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S, Takemoto M, Hiraki Y, Harada M, Tanimoto M, Okayama Lung Cancer Study Group (2003) Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89:795–802

    PubMed  Article  CAS  Google Scholar 

  23. Koukourakis MI, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S, Kotsakis A, Androulakis N, Bahlitzanakis N, Georgoulias V (1998) Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34:838–844

    PubMed  Article  CAS  Google Scholar 

  24. Iwasaki Y, Ohsugi S, Natsuhara A, Tsubokura T, Harada H, Ueda M, Arimoto T, Hara H, Yamada T, Takesako T, Kohno K, Hosogi S, Nakanishi M, Marunaka Y, Nishimura T (2006) Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 58:735–741

    PubMed  Article  CAS  Google Scholar 

  25. Wu HG, Bang YJ, Choi EK, Ahn YC, Kim YW, Lim TH, Suh C, Park K, Park CI (2002) Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:75–80

    PubMed  Article  CAS  Google Scholar 

  26. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT III, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR et al (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880–1892

    PubMed  CAS  Google Scholar 

  27. Guida C, Maione P, Rossi A, Bareschino M, Schettino C, Barzaghi D, Elmo M, Gridelli C (2008) Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development. Crit Rev Oncol Hematol 68:222–232

    PubMed  Article  Google Scholar 

  28. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gumerlock P, Kuebler JP, Bearden JD III, Crowley J, Livingston R, Southwest Oncology Group (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004–2010

    PubMed  Article  CAS  Google Scholar 

  29. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L, Hoosier Oncology Group, US Oncology (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology. J Clin Oncol 26:5755–5760

    PubMed  Article  CAS  Google Scholar 

  30. Semrau S, Klautke G, Fietkau R (2011) Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer after concurrent chemoradiotherapy: A single-center analysis of 161 Cases. Int J Radiat Oncol Biol Phys Int J Radiat Oncol Biol Phys 79:96–104

    Google Scholar 

  31. Huber RM, Borgmeier A, Flentje M, Willner J, Schmidt M, Manegold C, Bramlage P, Debus J (2010) Concurrent chemoradiation therapy with docetaxel/cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study. Clin Lung Cancer 11:45–50

    PubMed  Article  CAS  Google Scholar 

  32. Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374:379–386

    PubMed  Article  CAS  Google Scholar 

  33. Kaya AO, Buyukberber S, Benekli M, Coskun U, Sevinc A, Akmansu M, Yildiz R, Ozturk B, Yaman E, Kalender ME, Orhan O, Yamac D, Uner A, Anatolian Society of Medical Oncology (ASMO) (2010) Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Med Oncol 27:152–157

    PubMed  Article  CAS  Google Scholar 

  34. D’Angelillo RM, Trodella L, Ciresa M, Cellini F, Fiore M, Greco C, Pompeo E, Mineo TC, Paleari L, Granone P, Ramella S, Cesario A (2009) Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol 4:1517–1523

    PubMed  Article  Google Scholar 

Download references

Conflict of interest

The authors have declared no conflicts of interest.

Author information

Affiliations

  1. Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey

    Fatma Sen, Pinar Saip, Erkan Topuz & Adnan Aydiner

  2. Department of Radiation Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey

    Esra Kaytan Saglam, Ahmet Kizir, Ethem Nezih Oral & Barkin Sakallioglu

  3. Department of Thoracic Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Alper Toker & Sukru Dilege

Authors
  1. Fatma Sen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esra Kaytan Saglam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alper Toker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sukru Dilege
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmet Kizir
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ethem Nezih Oral
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pinar Saip
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Barkin Sakallioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Erkan Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Adnan Aydiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fatma Sen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sen, F., Saglam, E.K., Toker, A. et al. Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer. Cancer Chemother Pharmacol 68, 1497–1505 (2011). https://doi.org/10.1007/s00280-011-1642-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1642-8

Keywords

  • Cisplatin
  • Concomitant chemoradiotherapy
  • Consolidation
  • Docetaxel
  • Locally advanced disease
  • Non-small cell lung cancer
  • Surgery